BCR-ABL1 tyrosine kinase inhibitor K0706 exhibits preclinical activity in Philadelphia chromosome-positive leukemia

Patients with chronic-phase CML (CP-CML) are effectively managed with BCR-ABL1 tyrosine kinase inhibitors (TKIs), and their survival approaches that of age-matched controls [1]. K0706 was designed as a BCR-ABL1 TKI to provide an option for patients experiencing resistance or intolerance to the first-line TKIs imatinib, nilotinib, dasatinib, and bosutinib [2,3]. Structural elements that overlap with dasatinib and ponatinib are noted (Figure 1A).

Source: Experimental Hematology - September 3, 2019 Category: Hematology Authors: Orlando Antelope, Nadeem Vellore, Anthony D. Pomicter, Ami B. Patel, Alexandria van Scoyk, Phillip M. Clair, Michael Deininger, Thomas O'Hare Tags: Fast Track Submission Source Type: research